Kodiak Sciences: From Clinical Redemption to Platform-Levered Re-Rating
Kodiak (KOD) has moved from a survival story to a company capable of monetizing a differentiated retinal-therapy platform. The market has priced in some clinical progress — current valuation ($~2.06B market cap) assumes multi-indication potential — but Phase III execution and near-term regulatory milestones can drive a re-rate. This trade targets a…